

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2006 (28.12.2006)

PCT

(10) International Publication Number
WO 2006/137789 A1

(51) International Patent Classification:

C07D 215/52 (2006.01) A61P 25/22 (2006.01)
A61K 31/47 (2006.01) A61P 25/24 (2006.01)
A61P 11/06 (2006.01) A61P 25/28 (2006.01)
A61P 25/00 (2006.01) A61P 3/04 (2006.01)
A61P 25/18 (2006.01) A61P 35/00 (2006.01)

15437, Wilmington, DE 19850-5437 (US). **WOODS, James** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **LI, Yan** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US).

(21) International Application Number:

PCT/SE2006/000758

(74) Agent: **ASTRAZENECA**; Global Intellectual Property, S-151 85 Södertälje (SE).

(22) International Filing Date: 21 June 2006 (21.06.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/693,281 23 June 2005 (23.06.2005) US

(71) Applicant (for all designated States except US): **ASTRAZENECA** [SE/SE]; S-151 85 Södertälje (SE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SIMPSON, R. Thomas** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **KANG, James** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **ALBERT, S., Jeffrey** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **ALHAMBRA, Christobal** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box 15437, Wilmington, DE 19850-5437 (US). **KOETHER, M., Gerard** [US/US]; AstraZeneca Wilmington, 1800 Concord Pike, P.O. Box

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: Quinoline 3 -sulfonate esters as NK3 receptor modulators



(I)

(57) Abstract: Compounds of Formula I wherein R^1 , A, R^2 , R^3 , R^4 , R^5 , n, m and q are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.